What does Biostate AI do?
Biostate AI is an artificial intelligence company focused on leveraging generative AI and RNA sequencing technologies to predict the evolution of human disease and drug response. The company employs patented wetlab technologies such as BIRT to collect transcriptomic and genomic data at scale, making their approach both affordable and efficient.
How much did they raise?
The startup raised $12M in Series A funding, with Accel leading the round and participation from Gaingels, Mana Ventures, InfoEdge Ventures, Matter Venture Partners, Vision Plus Capital, Catapult Ventures, as well as angel investors including Dario Amodei, Mike Schnall-Levin, and Emily Leproust.
What are their plans for the money?
Biostate AI plans to use the funds to expand its operations and boost research and development efforts, potentially accelerating progress in predictive analytics for disease evolution and the development of new treatments.
What have they achieved so far?
The company has already made significant strides by developing proprietary and patented technologies like BIRT, enabling scalable and cost-effective collection of large volumes of transcriptomic and genomic data, which positions it well in the field of disease prediction.
